VIPoma overview: Difference between revisions
Homa Najafi (talk | contribs) |
Homa Najafi (talk | contribs) No edit summary |
||
| Line 25: | Line 25: | ||
==Natural History, Complications and Prognosis== | ==Natural History, Complications and Prognosis== | ||
If left untreated, patients with VIPoma may progress to develop watery [[diarrhea]], [[abdominal pain]], [[bloating]], [[nausea]], [[vomiting]], [[skin rash]], [[backache]], [[flushing]], and [[lethargy]]. Common complications of VIPoma include [[metastasis]], [[cardiac arrest]] from low blood [[potassium]] level, and [[dehydration]]. The presence of metastasis is associated with a particularly poor prognosis among patients with VIPoma, with a 5 year survival rate of 20% and 3 year survival rate of 40%. | If left untreated, patients with VIPoma may progress to develop watery [[diarrhea]], [[abdominal pain]], [[bloating]], [[nausea]], [[vomiting]], [[skin rash]], [[backache]], [[flushing]], and [[lethargy]]. Common complications of VIPoma include [[metastasis]], [[cardiac arrest]] from low blood [[potassium]] level, and [[dehydration]]. The presence of metastasis is associated with a particularly poor prognosis among patients with VIPoma, with a 5 year survival rate of 20% and 3 year survival rate of 40%. | ||
==History and Symptoms== | ==Diagnosis== | ||
===Diagnostic Study of Choice=== | |||
===History and Symptoms=== | |||
The hallmark of VIPoma is watery [[diarrhea]]. A positive history of [[abdominal pain]], [[weight loss]], [[numbness]], and [[weakness]] is suggestive of VIPoma. | The hallmark of VIPoma is watery [[diarrhea]]. A positive history of [[abdominal pain]], [[weight loss]], [[numbness]], and [[weakness]] is suggestive of VIPoma. | ||
==Physical Examination== | ===Physical Examination=== | ||
Common physical examination findings of VIPoma include [[tachycardia]], [[rash]], [[facial flushing]], [[abdominal tenderness]], and [[abdominal distention]]. | Common physical examination findings of VIPoma include [[tachycardia]], [[rash]], [[facial flushing]], [[abdominal tenderness]], and [[abdominal distention]]. | ||
==Laboratory Findings== | ===Laboratory Findings=== | ||
Laboratory tests used in the diagnosis of VIPoma include serum vasoactive intestinal polypeptide (VIP) levels, basal gastric acid output, potassium, bicarbonate, magnesium, and calcium levels. | Laboratory tests used in the diagnosis of VIPoma include serum vasoactive intestinal polypeptide (VIP) levels, basal gastric acid output, potassium, bicarbonate, magnesium, and calcium levels. | ||
==CT== | ===CT=== | ||
On CT scan VIPoma is characterized by hypervascularity with diffuse multiple metastatic nodulations. | On CT scan VIPoma is characterized by hypervascularity with diffuse multiple metastatic nodulations. | ||
==MRI== | ===MRI=== | ||
Abdominal MRI is helpful in the diagnosis of VIPoma. On abdominal MRI, VIPoma is characterized by a mass which is hypointense on T1-weighted MRI and hyperintense on T2-weighted MRI. | Abdominal MRI is helpful in the diagnosis of VIPoma. On abdominal MRI, VIPoma is characterized by a mass which is hypointense on T1-weighted MRI and hyperintense on T2-weighted MRI. | ||
==Echocardiography or Ultrasound== | ===Echocardiography or Ultrasound=== | ||
Abdominal ultrasound scan may be helpful in the diagnosis of VIPoma. Finding on ultrasound scan suggestive of VIPoma is hypoechoic tumor in the distal pancreas. | Abdominal ultrasound scan may be helpful in the diagnosis of VIPoma. Finding on ultrasound scan suggestive of VIPoma is hypoechoic tumor in the distal pancreas. | ||
==Other Imaging Findings== | ===Other Imaging Findings=== | ||
Other imaging studies for VIPoma include [[somatostatin]] receptor scintigraphy and PET scan. | Other imaging studies for VIPoma include [[somatostatin]] receptor scintigraphy and PET scan. | ||
===Other Diagnostic Studies=== | ===Other Diagnostic Studies=== | ||
Other [[diagnostic]] studies for VIPoma include [[immunohistochemical staining]] [[test]], which demonstrates [[staining]] for [[Marker|markers]] such as [[chromogranin A]], [[Cytokeratin|cytokeratin 19]], [[synaptophysin]], [[Ki-67]], [[Enolase|neuron specific enolase]], PGP 9.5. | Other [[diagnostic]] studies for VIPoma include [[immunohistochemical staining]] [[test]], which demonstrates [[staining]] for [[Marker|markers]] such as [[chromogranin A]], [[Cytokeratin|cytokeratin 19]], [[synaptophysin]], [[Ki-67]], [[Enolase|neuron specific enolase]], PGP 9.5. | ||
==Treatment== | |||
==Medical Therapy== | ===Medical Therapy=== | ||
Initial treatment in [[patient]] with VIPoma is [[prompt]] [[Fluid replacement therapy|replacement of fluid]] and correction of [[electrolyte imbalance]] and [[Acid-base disturbances|acid-base disturbance]]. [[Sandostatin|Somatostatin]] analogues like short acting [[octreotide]] is useful for controlling [[diarrhea]] by blocking the release of [[Vasoactive intestinal peptide|VIP]]. [[Octreotide]] is later replaced by longer acting depot preparation of [[somatostatin]] analogues like [[sandostatin]] or [[lanreotide]]. | Initial treatment in [[patient]] with VIPoma is [[prompt]] [[Fluid replacement therapy|replacement of fluid]] and correction of [[electrolyte imbalance]] and [[Acid-base disturbances|acid-base disturbance]]. [[Sandostatin|Somatostatin]] analogues like short acting [[octreotide]] is useful for controlling [[diarrhea]] by blocking the release of [[Vasoactive intestinal peptide|VIP]]. [[Octreotide]] is later replaced by longer acting depot preparation of [[somatostatin]] analogues like [[sandostatin]] or [[lanreotide]]. | ||
=== Interventions === | === Interventions === | ||
==Surgery== | ===Surgery=== | ||
[[Surgery]] is the [[mainstay]] of treatment for VIPoma. [[Surgery]] should be considered after initial [[symptomatic]] management of VIPoma [[inoperable]] cases. Complete [[surgical resection]] of the [[tumor]] is the only [[Cure|curative]] treatment for VIPoma. If the [[tumor]] cannot be removed completely, [[Surgery|surgical]] [[debulking]] may have [[Palliative therapy|palliative]] effect for [[control]] of [[hormonal]] [[symptoms]]. | [[Surgery]] is the [[mainstay]] of treatment for VIPoma. [[Surgery]] should be considered after initial [[symptomatic]] management of VIPoma [[inoperable]] cases. Complete [[surgical resection]] of the [[tumor]] is the only [[Cure|curative]] treatment for VIPoma. If the [[tumor]] cannot be removed completely, [[Surgery|surgical]] [[debulking]] may have [[Palliative therapy|palliative]] effect for [[control]] of [[hormonal]] [[symptoms]]. | ||
==Primary Prevention== | ===Primary Prevention=== | ||
There are no established [[Measurement|measures]] for the [[primary prevention]] of VIPoma. | There are no established [[Measurement|measures]] for the [[primary prevention]] of VIPoma. | ||
==Secondary Prevention== | ===Secondary Prevention=== | ||
Effective [[Measurement|measures]] for the [[secondary prevention]] of VIPoma include [[History and Physical examination|history and physical examination]], [[serum]] [[Vasoactive intestinal peptide|VIP]] levels and [[Indication (medicine)|indicated]] [[Marker|markers]], and multi-phasic [[Computed tomography|CT scan]] or [[MRI]]. | Effective [[Measurement|measures]] for the [[secondary prevention]] of VIPoma include [[History and Physical examination|history and physical examination]], [[serum]] [[Vasoactive intestinal peptide|VIP]] levels and [[Indication (medicine)|indicated]] [[Marker|markers]], and multi-phasic [[Computed tomography|CT scan]] or [[MRI]]. | ||
Revision as of 15:33, 3 October 2019
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma overview On the Web |
|
American Roentgen Ray Society Images of VIPoma overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]
Overview
VIPoma was first described in 1958 by Verner and Morrison. A VIPoma is a rare tumor of the non-beta cells of the pancreas that results in the overproduction of the hormone vasoactive intestinal peptide (VIP). On microscopic histopathological analysis, findings of VIPoma are composition of uniform, small to intermediate-sized cells in clusters, nests, and trabecular growth patterns with hyperchromatic nuclei and scant cytoplasm. There are no established causes for VIPoma. VIPoma must be differentiated from ganglioneuroblastoma, ganglioneuroma, factitious diarrhea, bile salt enteropathy, rectal vilous adenomas, and laxative abuse. The incidence VIPoma is approximately 0.01 per 100,000 individuals worldwide. Females are more commonly affected with VIPoma than male. The incidence of VIPoma increases with age, the median age at diagnosis is 50 years. The most common risk factor in the development of VIPoma is positive family history of multiple endocrine neoplasia type 1. If left untreated, patients with VIPoma may progress to develop watery diarrhea, abdominal pain, bloating, nausea, vomiting, skin rash, backache, flushing, and lethargy. Common complications of VIPoma include metastasis, cardiac arrest from low blood potassium level, and dehydration. The presence of metastasis is associated with a particularly poor prognosis among patients with VIPoma, with a 5 year survival rate of 20% and 3 year survival rate of 40%. The hallmark of VIPoma is watery diarrhea. A positive history of abdominal pain, weight loss, numbness, and weakness is suggestive of VIPoma. Common physical examination findings of VIPoma include tachycardia, rash, facial flushing, abdominal tenderness, and abdominal distention. Laboratory tests used in the diagnosis of VIPoma include serum vasoactive intestinal polypeptide (VIP) levels, basal gastric acid output, and basic metabolic pannel for potassium, bicarbonate, magnesium, and calcium levels. On CT scan VIPoma is characterized by hypervascularity with diffuse multiple metastatic nodulation. Abdominal MRI is helpful in the diagnosis of VIPoma. On abdominal MRI, VIPoma is characterized by a mass which is hypointense on T1-weighted MRI and hyperintense on T2-weighted MRI. Abdominal ultrasound scan may be helpful in the diagnosis of VIPoma. Finding on ultrasound scan suggestive of VIPoma is hypoechoic tumor in the distal pancreas. Other imaging studies for VIPoma include somatostatin receptor scintigraphy and PET scan. Initial treatment in patient with VIPoma is prompt replacement of fluid and electrolyte losses. Steroids may be used to provide symptomatic relief. Surgery is the mainstay of treatment for VIPoma. Secondary prevention measures of VIPoma include a detailed history, physical examination, and imaging every 3 to 12 months up to one year post resection and every 6 to 12 months thereafter.
Historical Perspective
VIPoma which is also known as Verner-Morrison syndrome was first described in 1958 by Verner and Morrison.
Pathophysiology
A VIPoma is a rare tumor of the non-beta cells of the pancreas that results in the overproduction of the hormone vasoactive intestinal peptide (VIP). On microscopichistopathological analysis, findings of VIPoma are composition of uniform, small to intermediate-sized cells in clusters, nests, and trabecular growth patterns with hyperchromatic nuclei and scant cytoplasm.
Causes
The cause of VIPoma has not been identified.
Differentiating VIPoma From Other Diseases
VIPoma must be differentiated from ganglioneuroblastoma, ganglioneuroma, factitious diarrhea, bile salt enteropathy, rectal vilous adenomas, and laxative abuse.
Epidemiology and Demographics
The annual incidence of VIPoma is approximately 0.01 per 100,000 (approx. 1 in 10 million) individuals worldwide. Female are more commonly affected by VIPoma than male. The incidence of VIPoma increases with age, the median age at diagnosis in adults is 50 years. VIPoma in children is usually diagnosed between age 2 to 4.
Risk Factors
The most common risk factor in the development of VIPoma is positive family history of multiple endocrine neoplasia type 1.
Screening
According to the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for VIPoma.
Natural History, Complications and Prognosis
If left untreated, patients with VIPoma may progress to develop watery diarrhea, abdominal pain, bloating, nausea, vomiting, skin rash, backache, flushing, and lethargy. Common complications of VIPoma include metastasis, cardiac arrest from low blood potassium level, and dehydration. The presence of metastasis is associated with a particularly poor prognosis among patients with VIPoma, with a 5 year survival rate of 20% and 3 year survival rate of 40%.
Diagnosis
Diagnostic Study of Choice
History and Symptoms
The hallmark of VIPoma is watery diarrhea. A positive history of abdominal pain, weight loss, numbness, and weakness is suggestive of VIPoma.
Physical Examination
Common physical examination findings of VIPoma include tachycardia, rash, facial flushing, abdominal tenderness, and abdominal distention.
Laboratory Findings
Laboratory tests used in the diagnosis of VIPoma include serum vasoactive intestinal polypeptide (VIP) levels, basal gastric acid output, potassium, bicarbonate, magnesium, and calcium levels.
CT
On CT scan VIPoma is characterized by hypervascularity with diffuse multiple metastatic nodulations.
MRI
Abdominal MRI is helpful in the diagnosis of VIPoma. On abdominal MRI, VIPoma is characterized by a mass which is hypointense on T1-weighted MRI and hyperintense on T2-weighted MRI.
Echocardiography or Ultrasound
Abdominal ultrasound scan may be helpful in the diagnosis of VIPoma. Finding on ultrasound scan suggestive of VIPoma is hypoechoic tumor in the distal pancreas.
Other Imaging Findings
Other imaging studies for VIPoma include somatostatin receptor scintigraphy and PET scan.
Other Diagnostic Studies
Other diagnostic studies for VIPoma include immunohistochemical staining test, which demonstrates staining for markers such as chromogranin A, cytokeratin 19, synaptophysin, Ki-67, neuron specific enolase, PGP 9.5.
Treatment
Medical Therapy
Initial treatment in patient with VIPoma is prompt replacement of fluid and correction of electrolyte imbalance and acid-base disturbance. Somatostatin analogues like short acting octreotide is useful for controlling diarrhea by blocking the release of VIP. Octreotide is later replaced by longer acting depot preparation of somatostatin analogues like sandostatin or lanreotide.
Interventions
Surgery
Surgery is the mainstay of treatment for VIPoma. Surgery should be considered after initial symptomatic management of VIPoma inoperable cases. Complete surgical resection of the tumor is the only curative treatment for VIPoma. If the tumor cannot be removed completely, surgical debulking may have palliative effect for control of hormonal symptoms.
Primary Prevention
There are no established measures for the primary prevention of VIPoma.
Secondary Prevention
Effective measures for the secondary prevention of VIPoma include history and physical examination, serum VIP levels and indicated markers, and multi-phasic CT scan or MRI.
References